Approximately 25%–30% of NSCLC patients exhibit high PD-L1 expression (tumor proportion score, TPS ≥ 50%) and can benefit from a first-line therapy, for instance, with pembrolizumab [204]. Here, CD274 is linked to non-small cell lung carcinoma.